Project

1. Artificial Exosome-Anti Cancer Drug
- Use of novel and conventional cytotoxic compounds
- Use of bio therapeutics (siRNA, peptides)
2. Autologous Artificial Exosome Therapy
- Artificial Exosome derived from cancer patient immune cells
3. Stem cell derived Artificial Exosome Therapy
- Artificial Exosome derived from Stem cells
4. Artificial Exosome-Imaging Probes
- Use of novel and conventional probes
- Collaboration research is preferred

Project Summary

Exosome, a nano-vesicle secreted by cells such as immune cells and stem cells. Its main function is to regulate intercellular communication in human body. Exosome has recently attracted attention as a next-generation drug delivery system because of its specific targeting function. However, based on the existing technology, it is difficult to commercialize them because the amount of exosome secreted by cells is insufficient. MDimune has recently developed the “BioDroneTM Technology" for producing artificial exosomes in bulk. This technology can overcome the current limitation of low yield exosomes secreted by cells.

Business Model

MDimune Inc. is founded in 2015. The key technology of MDimune is “BioDroneTM technology” which is a target specific drug delivery platform based on artificial exosomes derived from human cells. By using the “BioDroneTM Technology platform, we are developing innovative therapeutics drug to solve the unmet medical needs.
Our Business Model is based on "PIDO". PIDO means Platform Inside Development Outside. Hence, we aim to acquire this platform-based technology to overcome the limitation of current medical problems and transfer the technology based on partnerships.
1. Profit: Technology license out and co-development
2. Key customer: Hospital (Cancer patient and intractable patient)
3. Main Channel: Patient specific cancer and intractable disease treatment center
4. Core Activity: Establishment of artificial exosome production process and create partnerships networking with Hospitals
5. Overseas Expansion: Expected to expand and distribute to China, Japan, etc.

Main Achievements

1. Technology patent has been successfully registered in Korea, China, and Japan and the application is under reviewing in the U.S. and EU. We also filed four trademark applications for this technology.
2. Two government research grants, anti-cancer drug development based on artificial exosomes derived and allogenic immune cells are being carried out.
3. MDimune is expanding collaboration with biotech, pharmaceutical companies, and hospitals for the potential applications of the BioDroneTM Technology.